Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BSB202301

SN-38 Polymeric Nanoparticle (new formulation)

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: SN-38 Polymeric Nanoparticle (new formulation)
    Indications: Solid tumor,Lung cancer
    Research phase: Phase II
    Cooperation demands: Global and Regional Out-licensing
  • Highlights

    1. Project profile


    Project name: SN-38 Polymeric Nanoparticle (new formulation)


    Indications: Solid Tumor (Lung Cancer)


    Research phase: Phase 1b/2a (USA, KR)


    Cooperation demands: Global and Regional Out-licensing


    2. Highlights


    Viscous Gel Temozolomide


    I) Superior Safety: “Asset” has significantly less diarrhea and neutropenia, which aremajor side effect of Irinotecan.


    No DLT (dose limiting toxicity) such as diarrhea


    Not reached MTD (maximum tolerable dose) yet


    Promising candidate for combination with other drugs



    II) Superior Efficacy: Asset showed superior efficacy in SCLC, and NSCLC compared to competitive products in phase 1a clinical trial. Subgroup analysis (lung cancer) results: DCR is 4/5 (80%), ORR is 2/5 (40%), these patients were all treated by “asset” as 3rd, 4th or 5th-line Treatment.


    Zepzelca® (lurbinectedin) became a blockbuster in SCLC by beating former standard of care Hycamtin® (topotecan), While “asset” can have the potential to surpass these two competitors. “Asset” has received Orphan Drug Designation by FDA.

  • Project Introduction

    1. Asset type: SN-38 Polymeric Nanoparticle

    2. Indication: Solid Tumor (Lung Cancer)

    3. Modality: Small molecule

    4. Research: Phase 1b/2a (USA, KR)

    5. Demands: Global and Regional Out-licensing

    Research progress:

    (1) Asset showed superior efficacy in SCLC, and NSCLC compared to competitive products in phase 1a clinical trial.

    (2) Extension of indication and highly successful Phase 2 Study.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message